
More information is needed on a weight-loss jab’s effectiveness in treating type 2 diabetes before it is recommended for NHS use, the National Institute for Health and Care Excellence (Nice) has said.
The recommendation for tirzepatide, which is sold under the brand name Mounjaro and is developed by Eli Lilly, was issued in draft guidance issued by the public body.